BD Names Nikos Pavlidis President of Diagnostic Solutions

FRANKLIN LAKES, **N.J.** (**Feb. 28**, **2024**) – BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announced today that Nikos Pavlidis has been named president of BD Diagnostic Solutions.

Pavlidis will be responsible for driving global strategic, operational, commercial performance and customer experience across the Diagnostic Solutions business, including molecular diagnostics, microbiology and point-of-care platforms. He will report to Dave Hickey, executive vice president (EVP) and president of the Life Sciences Segment. Pavlidis has been serving as acting president of Diagnostic Solutions since November 2023 and previously served in roles including vice president and general manager for the Diagnostics business group, and various global and regional marketing leadership roles for BD.

"Having dedicated more than two decades working closely with health care professionals, Nikos understands the value and impact of diagnostics in clinical decision-making in high- and mid-throughput labs, as well as the shift to non-traditional care settings, including home and retail locations," said Hickey. "Nikos brings a level of domain knowledge and expertise that is highly valued by the business and will be critical to our focus on the key needle movers in achieving our strategy to deliver diagnostic tests, instrumentation, automation and informatics."

Pavlidis has been with BD for nearly 25 years and has held various customer support, sales and marketing roles within Europe, including leading the BD Diagnostic Systems commercial organizations across Northwest Europe. In 2013, Pavlidis joined the global Diagnostic Systems organization and relocated to the division's global headquarters in Sparks, Maryland.

He serves on the University of Maryland Foundation Board of Trustees and holds a bachelor's degree in biomedical engineering from the University of Athens in Greece as well as a Master of Science in biomedical engineering from the University of Dundee in the United Kingdom.

About BD

BD is one of the largest global medical technology companies in the world and is advancing the world of health by improving medical discovery, diagnostics and the delivery of care. The company supports the heroes on the frontlines of health care by developing innovative technology, services and solutions that help advance both clinical therapy for patients and clinical process for health care providers. BD and its more than 70,000 employees have a passion and commitment to help enhance the safety and efficiency of clinicians' care delivery process, enable laboratory scientists to accurately detect disease and advance researchers' capabilities to develop the next generation of diagnostics and therapeutics. BD has a presence in virtually every country and partners with organizations around the world to address some of the most challenging global health issues. By working in close collaboration with customers, BD can help enhance outcomes, lower costs, increase efficiencies, improve safety and expand access to health care. For more information on BD, please visit bd.com or connect with us on LinkedIn at www.linkedin.com/company/bd1/, X (formerly Twitter) @BDandCo or Instagram @becton_dickinson

Contacts:

 Media:
 Investors:

 Troy Kirkpatrick
 Adam Reiffe

 VP, Public Relations
 Sr. Director, Investor Relations

 858.617.2361
 201.847.6927

 troy.kirkpatrick@bd.com adam.reiffe@bd.com

Additional assets available online: Additional assets available online: Additional assets available online:

https://news.bd.com/2024-02-28-BD-Names-Nikos-Pavlidis-President-of-Diagnostic-Solutions